Lv61
1659 积分 2021-01-31 加入
Antibody–drug conjugates: Recent advances in linker chemistry
30天前
已完结
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates
30天前
已完结
Risk Evaluation of N-Nitrosamines in Drug-Linker Intermediates Used To Generate Antibody–Drug Conjugates
30天前
已完结
Industry Perspective on the Selection of Regulatory Starting Materials for Synthetic Peptides
30天前
已完结
Impact of ICH Q11 Questions and Answers on the Outcome of Active Pharmaceutical Ingredient Starting Material Proposal Acceptance by ICH Regulatory Members
30天前
已完结
Harnessing biosynthetic logic for next-generation ADC payloads
30天前
已完结
Process Development for a TLR-7 Immunostimulatory Drug-Linker: Salt Screening and Precipitation for Drug-Linker Intermediates
30天前
已完结
Purge Factor Analysis and Proposal for Non-conjugatable Impurity Clearance in Post-conjugation Purification of ADCs
30天前
已完结
Discovery of Novel N-Linked Camptothecin Linker-Payloads to Access Antibody-Drug Conjugates with High Target-Mediated In Vivo Efficacy
30天前
已完结
Global landscape analysis of antibody-drug conjugate clinical trials for prostatic neoplasms: current status, opportunities and challenges
30天前
已完结
皖公网安备34019202002308
